Functional Consequences of Metabolic Zonation in Murine Livers: Insights for an Old Story

Nikolaus Berndt 1*, Erik Kolbe, 2* Robert Gajowski, 3,4 Johannes Eckstein, 5 Fritz Ott, 2 David Meierhofer, 3 Hermann-Georg Holzhütter, 5** and Madlen Matz-Soja 2,6**

BACKGROUND AND AIMS: Zone-dependent differences in expression of metabolic enzymes along the portocentral axis of the acinus are a long-known feature of liver metabolism. A prominent example is the preferential localization of the enzyme, glutamine synthetase, in pericentral hepatocytes, where it converts potentially toxic ammonia to the valuable amino acid, glutamine. However, with the exception of a few key regulatory enzymes, a comprehensive and quantitative assessment of zonal differences in the abundance of metabolic enzymes and, much more important, an estimation of the associated functional differences between portal and central hepatocytes is missing thus far.

APPROACH AND RESULTS: We addressed this problem by establishing a method for the separation of periportal and pericentral hepatocytes that yields sufficiently pure fractions of both cell populations. Quantitative shotgun proteomics identified hundreds of differentially expressed enzymes in the two cell populations. We used zone-specific proteomics data for scaling of the maximal activities to generate portal and central instantiations of a comprehensive kinetic model of central hepatic metabolism (Hepatokin1).

CONCLUSIONS: The model simulations revealed significant portal-to-central differences in almost all metabolic pathways involving carbohydrates, fatty acids, amino acids, and detoxification. (Hepatology 2021;73:795-810).

The liver is the central metabolic organ of higher vertebrates and continuously adapts its metabolic capacities to the actual physiological status of the individual. After a carbohydrate-rich meal, a substantial portion of glucose is taken up by the liver from the plasma and is transiently converted into glycogen and triacylglycerol. Conversely, under fasting conditions, the liver produces glucose by phosphorolysis of glycogen and de novo synthesis from amino acids, lactate, and glycerol to prevent a potentially life-threatening drop in plasma glucose below 55 mg/dL. (1) Intriguingly, the capacity of hepatocytes to take up or to produce glucose varies with their location within the liver acinus. Hepatocytes close to the...
portal vein (periportal hepatocytes; PPHs) possess a higher gluconeogenic capacity than hepatocytes close to the central vein (pericentral hepatocytes; PCHs). Conversely, PCHs have a higher glycolytic capacity than PHHs. Gradual spatial separation of anabolic (ATP-consuming) gluconeogenesis from catabolic (ATP-generating) glycolysis may represent a principle in tissue metabolism to limit the extent of ATP-wasting futile cycles. Another prominent example of zone-dependent metabolic differences is ammonia detoxification. Ammonia fixation in urea is predominantly located in the periportal (PP) zone, whereas glutamine synthesis is predominantly located in the pericentral (PC) zone.\(^{(2,3)}\)

Zonal differences in the proteome of hepatocytes are driven by portocentral gradients of oxygen, metabolites (e.g., glucose), hormones and morphogens such as Wnt, Hedgehog, and hepatocyte nuclear factor alpha.\(^{(4,5)}\) The opposing effects of the pancreatic hormones, insulin and glucagon, on the zonation of glycolytic and glucogenic enzymes have been demonstrated in the earlier pioneering in vitro studies of Jungermann.\(^{(6)}\) Subsequently, flow bioreactors were used to study the impact of selected regulators of zonation by exposing hepatocytes to controlled concentrations gradients of oxygen, metabolites, or xenobiotics.\(^{(7,8)}\) Using a tissue model of the liver acinus and taking into account known relationships between the protein translation rate and oxygen, glucose, insulin, and glucagon concentrations, we were able to recapitulate the zonation of hepatic glucose metabolism under fasting and feeding conditions.\(^{(9)}\)

Over several decades, the investigation of differential gene expression along the portocentral axis has been restricted to a few key regulatory enzymes. More recently, the group of Shalev Itzkovitz was successful in quantifying the entire transcriptome of thousands of mouse liver cells together with their lobule coordinates.\(^{(10)}\) They found that ~50% of liver genes are significantly zonated, but a comprehensive and quantitative analysis of the functional consequences of this zone-specific enrichment was not provided in this pioneering work. Therefore, we have strived to map the zone-dependent expression data for metabolic enzymes and membrane transporters onto a mechanistic model of the central hepatic metabolism. Therefore, we isolated hepatocytes from mouse liver by collagenase perfusion and separated PPHs and PCHs by immunostaining and subsequent cell sorting. We then used shotgun proteomics to explore the proteome of the purified hepatocytes. Specifically, we used relative protein abundances to scale the maximal activities of enzymes and membrane transporters included in a recently published kinetic model of hepatocyte metabolism\(^{(11)}\) to assess the implications of zone-dependent gene expression for a multitude of different metabolic functions (Fig. 1). A complete list of all enzymes and transporters considered in the model is given in Supporting Table S1.

**ARTICLE INFORMATION:**

From the 1Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute for Imaging Science and Computational Modelling in Cardiovascular Medicine, Berlin, Germany; 2Rudolf-Schönheimer-Institute of Biochemistry, Faculty of Medicine, Leipzig University, Leipzig, Germany; 3Max Planck Institute for Molecular Genetics, Berlin, Germany; 4Department of Biology, Chemistry, Pharmacy, Freie Universität, Berlin, Germany; 5Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Biochemistry, Berlin, Germany; 6Division of Hepatology, Department of Oncology, Gastroenterology, Hepatology, Pulmonology, and Infectious Diseases, Leipzig University Medical Center, Leipzig, Germany.

**ADDRESS CORRESPONDENCE AND REPRINT REQUESTS TO:**

Nikolaus Berndt, PD
Charité – Universitätsmedizin Berlin
Institute for Imaging Science and Computational Modelling in Cardiovascular Medicine
Augustenburger Platz 1
13353 Berlin, Germany
E-mail: nikolaus.berndt@charite.de
Tel.: +4930450528466
FIG. 1. Schematic model representation. Reactions and transport processes between compartments are symbolized by arrows. Single pathways as defined in biochemical text books are numbered and highlighted by different coloring: (1) glycogen metabolism, (2) fructose metabolism, (3) galactose metabolism, (4) glycolysis, (5) gluconeogenesis, (6) oxidative pentose phosphate pathway, (7) nonoxidative pentose phosphate pathway, (8) fatty acid synthesis, (9) triglyceride synthesis, (10) synthesis and degradation of lipid droplets and synthesis of VLDL lipoprotein, (11) cholesterol synthesis, (12) tricarboxylic acid (TCA) cycle, (13) respiratory chain and oxidative phosphorylation, (14) β-oxidation of fatty acids, (15) urea cycle, (16) ethanol metabolism, (17) ketone body synthesis, (18) ammonia formation, (19) serine utilization, and (20) alanine utilization. Small cylinders and cubes symbolize ion channels and ion transporters. Double arrows indicate reversible reactions, which may proceed in both directions according to the value of the thermodynamic equilibrium constant and cellular concentrations of their reactants. Reactions are labeled by the short names of the catalyzing enzyme or membrane transporter given in the small boxes attached to the reaction arrow. Red boxes indicate enzymes that are regulated by hormone-dependent reversible phosphorylation. Metabolites are denoted by their short names. Full names of metabolites and kinetic rate laws of reaction rates are outlined in Berndt et al. (13)
Materials and Methods

ISOLATION OF PRIMARY MOUSE HEPATOCYTES

Primary hepatocytes were isolated by collagenase perfusion of mouse liver as described in an earlier work.\(^1\) Isolated hepatocytes were cleared of nonparenchymal cells by differential centrifugation.\(^2\) We have demonstrated the purity of our primary hepatocyte isolation by this method elsewhere, where we looked for the expression of typical markers of mature hepatocytes such as \textit{Arg1} (arginase 1), \textit{Gck} (glucokinase), \textit{Glis2} (glutaminase 2 [liver, mitochondrial]), \textit{Ldha} (lactate dehydrogenase A chain), \textit{Krt18} (keratin 18), and \textit{Krt8} (keratin 8). For the nonparenchymal cell population (e.g., hepatic stellate cells, vascular smooth muscle cells, Kupffer cells, and cholangiocytes), we analyzed \textit{Gfap} (glial fibrillary acidic protein), \textit{Acta2} (actin, alpha 2, smooth muscle, aorta), \textit{Emr1} (EGF-like module containing, mucin-like, hormone receptor-like sequence 1), and \textit{Krt19} (keratin 19).\(^2\)

MAINTENANCE OF THE MICE AND FEEDING

Male C57Bl/6N mice were maintained in a pathogen-free facility. The animals were kept on a 12:12 h LD cycle, according to the German guidelines, the World Medical Association and the Declaration of Helsinki for the care and safe use of experimental animals. The mice had free access to regular chow (ssniff M-Z V1124-0, composed of 22.0% protein, 50.1% carbohydrate, 4.5% fat; usable energy: 13.7 kJ/g; ssniff Spezialdiäten GmbH, Germany) and tap water throughout the experiment. The C57Bl/6N mice were sacrificed at 3 months of age, between 9:00 and 11:00 am, after administration of an anesthetic mixture of ketamine, xylazine and atropine. Other detailed methods are available in the Supporting Information.

Results

ISOLATION OF PP AND PERICENTRAL HEPATOCYTES BY FLOW CYTOMETRY

To sort the isolated primary hepatocytes into populations of PPHs and PCHs, specific marker proteins with no overlap in zonal expression (Fig. 2A) were chosen for intracellular staining. After excluding cell doublets in the forward scatter-area versus forward scatter-height plot and cell debris in the forward scatter versus side scatter plot, positive cell populations were gated against matching isotype controls (Supporting Figs. S1 and S2). The relative proportion of positively labeled cells in both stainings reflects the extended PP pattern of E-cadherin (E-cad), in contrast to the small, one-cell-layer PC localization of glutamine synthetase (GLUL), as indicated by immunohistochemistry staining (Supporting Fig. S3). E-Cad labeling (Supporting Fig. S3, left panel) resulted in large populations of \(~30\%-50\%\), whereas GLUL labeling (Supporting Fig. S3, right panel) resulted in small populations of \(~1.5\%-3.0\%\). To give a global overview about the purity of the sorting method, the data from proteome analysis were analyzed with regard to all proteins of the individual cell fractions. The results of this analysis show that 995 proteins (Supporting Table S2, sheet 3 and sheet 4) of a total of 3,736 (Supporting Table S3) detected proteins have a significant zonated pattern. A selection of the 40 most potent zonated proteins shows that well-known zonated proteins can be found in both the PC and the PP fraction (Fig. 2B; Table 1). Also, western blotting analysis of PPH and PCH marker proteins demonstrated the purity of the isolation method. Therefore, prominent PC-expressed proteins, such as GLUL, cytochrome P450 1A2 (CYP1A2), and cytochrome P450 2E1 (CYP2E1), could not, or could only weakly, be found in PPHs. The dominant PP-expressed protein, E-Cad, could not be detected in the PC fraction. Expression of carbamoyl-phosphate synthase 1 (CPS1) showed stronger expression in the PP zone; however, this protein is also found in PCHs (Fig. 2C,D). This corresponds to the rather homogeneous distribution of this protein, in which there is a tendency toward expression only in the PP region.\(^4\) In addition, Gaasbeek et al. showed that in the adult rat liver, some PC hepatocytes harbor also carbamoylphosphate synthetase, albeit the number of glutamine-synthetase–positive cells diminishes.\(^5\)

DIFFERENCES IN THE PROTEIN ABUNDANCES OF PPHs AND PCHs

Shotgun proteome profiling yielded protein intensities for 3,736 proteins that could be identified in PPHs, PCHs, and the reference hepatocytes. Statistical
FIG. 2. Sorting of PC and PP hepatocytes by flow cytometry. (A) Immunofluorescence double staining shows distinct PP (E-Cad, magenta) or PC (GLUL, green) location along the portocentral axis. (B) Fold-change heatmap of the 39 strongest zonated proteins. Red boxes indicate out-of-range values (>15-fold expression). The fold change of PPH and PCH cell populations to each other was calculated with the normalized LFQ intensities from the proteomic analysis. (C) Western blotting analysis of zone-specific markers in lysates from sorted GLUL-positive (PCHs; n = 3) and E-cad-positive (PPHs; n = 3) hepatocytes. (D) Western blotting protein quantification normalized to total protein. Unpaired t-test, *P ≤ 0.05. Abbreviations: AADAT, aminoadipate aminotransferase; ACOT11, acyl-coenzyme A thioesterase 11; CHPT1, choline phosphotransferase 1; CYP2A5/4, cytochrome P450, family 2, subfamily a, polypeptides 5 and 4; CYP2F2, cytochrome P450, family 2, subfamily f, polypeptide 2; CYP4A10/32, cytochrome P450, family 4, subfamily a, polypeptides 10 and 32; CYP4A14, cytochrome P450, family 4, subfamily a, polypeptide 14; CYP2C37, cytochrome P450, family 2. subfamily c, polypeptide 37; CYP2C50, cytochrome P450, family 2, subfamily c, polypeptide 50; CYP2C54, cytochrome P450, family 2, subfamily c, polypeptide 54; FAHD2, fumarylacetoacetate hydrolase domain-containing protein 2; GBA2, glucosylceramidase beta 2; GNB1, G protein subunit beta 1; IKBKKG, inhibitor of nuclear factor kappa B kinase regulatory subunit gamma; PLCG1, phospholipase C gamma 1; pv, P value; SLC1A2, solute carrier family 1 member 2; SLC25A25, solute carrier family 25, solute carrier family 25 member 25; SLC6A13, solute carrier family 6 member 13; SLC7A2, solute carrier family 7 member 2; SMPD2, sphingomyelin phosphodiesterase 2; ST6GAL1, ST6 beta-galactoside alpha-2,6-sialyltransferase 1; TMCO1, transmembrane and coiled-coil domains protein 1; URAH, 5-hydroxyisourate hydrolase; WDR91, WD repeat domain 91.
| Protein IDs | Protein Names                                      | Mean LFQ E-Cad Mouse 1-6 | Mean LFQ GLUL Mouse 1-6 |
|------------|----------------------------------------------------|--------------------------|-------------------------|
| P16045     | Galectin-1                                         | 0.00E+00                 | 1.40E+07                |
| Q69Z3;81AW3| Nonlysosomal glucosylceramidase                    | 0.00E+00                 | 3.01E+06                |
| A3KG44;Q8V091;E9Q2Y3;Q7TSS3;O88S22; A3KG40;A3KG41;A3KG38 | Nf-kappa-B essential modulator                      | 0.00E+00 | 5.28E+06 |
| A7U171;A2AU4 | Protein Shroom2                                      | 0.00E+00                 | 4.17E+06                |
| A2A4A6;Q62077;G3UXP4;F6SSL0 | Phosphoinositide phospholipase C1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.00E+00 | 6.03E+06 |
| A0A0R4J094;Q3TC72 | Fumarylacetoacetate hydrolase domain-containing protein 2A | 0.00E+00 | 1.37E+07 |
| S4R1X1;Q7TMQ7;D3Z101;D3Z0V8 | WD repeat-containing protein 91 | 0.00E+00 | 1.49E+07 |
| Q8CO25;D6RCW3;D3Z6W4;D3YU39 | Cholinephosphotransferase 1 | 0.00E+00 | 2.41E+07 |
| Q64505 | Cholesterol 7-alpha-monoxygenase                   | 0.00E+00                 | 1.69E+07                |
| P430D6;A2APL5;F6ZIK3;F7CAM6;A2AQI7 | Excitatory amino acid transporter 2;Amino acid transporter | 0.00E+00 | 9.49E+07 |
| P29758 | Ornithine aminotransferase, mitochondrial           | 2.53E+07 | 6.29E+09 |
| Q91X75;P20852;P15392;F7B9W9;F6SHL3;E9Q593 | Cytochrome P450 2A5;Cytochrome P450 2A4 | 9.41E+06 | 1.33E+09 |
| P15105;D3YVK1;D3Z121 | Glutamine synthetase                             | 3.60E+08 | 3.13E+10 |
| P56654 | Cytochrome P450 2C37                              | 2.33E+07                 | 9.19E+08                |
| A2A977;Q88832;A2A8T1;F8WGU9;A2A8S9; Q91U1;A2A6S8 | Cytochrome P450 4A10 | 8.75E+06 | 2.34E+08 |
| Q35728;A0A0B7W15 | Cytochrome P450 4A14 | 1.03E+07 | 1.97E+08 |
| Q64484;Q3UT49;H8RLM0 | Cytochrome P450 2C29 | 2.04E+08 | 3.28E+09 |
| A2ARh6;Q8VW9Q;F6SS2;EOCYSO; EOCYAO;EOCXP8 | Acyl-coenzyme A thioesterase 11 | 5.23E+05 | 7.76E+06 |
| A0A1BOGSS0;Q9CR83;A0A1BOGRP99; A0A0AMQ03 | 5-hydroxysisourate hydrolase | 1.29E+07 | 1.78E+08 |
| Q91X77 | Cytochrome P450 2C50                              | 3.73E+08                 | 4.58E+09                |
| P62874;H3BK2;H3BLF7;Q61O11 | Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 | 1.16E+07 | 1.34E+07 |
| Q05421;A0A1BOG5V7;Q0PGA1 | Cytochrome P450 2E1 | 2.63E+08 | 3.03E+09 |
| O70572;D6RM4 | Sphingomyelin phosphodiesterase 2 | 9.86E+05 | 1.12E+07 |
| Q9WWMB;Q3UNS8 | Kynurenine/alpha-aminoacidipate aminotransferase, mitochondrial | 7.50E+06 | 8.36E+07 |
| P00186 | Cytochrome P450 1A2                              | 3.82E+08                 | 4.25E+09                |
| Q66VU9 | Cytochrome P450 2C54                              | 7.58E+07                 | 8.35E+08                |
| A2ASZ8;Z4UL99;A0A0A6YWC1;F6RC04 | Calcium-binding mitochondrial carrier protein SCoMC-2 | 1.28E+07 | 1.26E+06 |
| A0A0A6YVS2;Q91L13 | Transmembrane and coiled-coil domain-containing protein 1 | 3.94E+07 | 3.85E+06 |
| P33267;A0A0U1RPL9 | Cytochrome P450 2F2 | 3.10E+09 | 2.39E+08 |
| Q64635 | Beta-galactoside alpha-2,6-sialytransferase 1       | 7.43E+06                 | 5.39E+05                |
| Q99JR1 | Sideroflexin-1                                    | 7.85E+08                 | 5.69E+07                |
| P31649;D3YWZ5 | Sodium- and chloride-dependent GABA transporter 2 | 1.95E+07 | 1.04E+06 |
| P35492;F8W7H3 | Histidine ammonia-lyase                             | 1.13E+09                 | 4.20E+07                |
| Q99RO2 | 17-beta-hydroxysteroid dehydrogenase type 6        | 1.04E+08                 | 2.28E+06                |
| O70570;D3YW4M;D3Z203 | Polymeric immunoglobulin receptor;Secretory component | 6.31E+07 | 6.15E+05 |
| E9Q1Y0;P18581 | Cationic amino acid transporter 2 | 6.82E+06 | 0.00E+00 |
| A0A140LU4;P56392 | Cytochrome c oxidase subunit 7A1, mitochondrial | 1.31E+07 | 0.00E+00 |
| A0A0R4IZW5;P09803 | Cadherin-1;E-Cad/CTF1;E-Cad/CTF2;E-Cad/CTF3 | 1.78E+07 | 0.00E+00 |
analysis of differences between the protein intensities in PPHs and PCHs by means of paired-sample t test at a significance level of $P = 0.05$ revealed that 21.9% of the detected proteome was zonated. There were only marginal differences in the percentage of proteins with higher expression levels in either the PPHs (13.4%) or the PCHs (13.2%).

From the whole detected proteome, we selected 316 proteins that are associated with enzymes and membrane transporters of the kinetic model (i.e., “model proteins”). Within this subgroup, 58.2% of proteins exhibited significant portal-to-central expression differences, which was more than twice as high as in the total proteome. Moreover, a larger fraction of metabolic enzymes had higher protein abundances in PPHs (42.7%), whereas the fraction of metabolic enzymes with higher expression in the PCHs was 22.5%. A complete list of differentially expressed proteins can be found in Supporting Table S2.

PARAMETERIZATION OF ZONE-SPECIFIC KINETIC MODELS

To obtain zone-specific instantiations of the metabolic model for each laboratory animal, the maximal activities of enzymes and transporters in the PCHs and PPHs were computed according to Equation 1 (see Materials and Methods). The average percentage of enzymes and transporters for which a protein intensity value was available from the proteomics analysis was 80.0%, with the lowest coverage of 64.4% and the highest coverage of 88.5%. To fill the gaps, we applied a statistical imputation method that estimates missing values of a given target protein based on the expression profiles of other predictor proteins with sufficiently similar intensity profiles taken from the same proteome. This method increased the average coverage of measured protein intensity values to 84.1%, with 77.9% the lowest coverage and 88.5% the highest coverage.

First, we compiled a list of potential predictor proteins for which measured protein intensities for the three cell fractions (PP, PC, or whole liver) were available for all 6 mice. This resulted in three sets of 1,482, 1,571, and 1,064 predictor proteins. Second, for a given target protein with missing protein intensity values in some mice, we determined a group of significantly Pearson-correlated ($P < 0.05$) predictor proteins also exhibiting a Spearman correlation larger than a critical threshold value $\rho > 0.95$. Linear regression analysis with each of these predictor proteins yielded estimates of the missing values. Finally, the missing intensity values were filled by the mean of the estimates obtained for all predictor proteins. For the 6 mice included in this study, the measured and imputed label-free quantification (LFQ) intensities for the proteins of the kinetic model are available for the reference cells, PPHs and PCHs in Supporting Table S4.

MODEL-BASED FUNCTIONAL CHARACTERIZATION OF PPHs AND PCHs

For the assessment of functional differences between PPHs and PCHs, we used zone-specific kinetic models to compute steady-state load characteristics describing the change of a metabolic function in response to changes in the concentration of a distinct plasma metabolite. Steady-state model computations assume that the characteristic time for the change of the plasma metabolites is much longer than the characteristic time required for establishing a stationary state of the metabolic network where the time derivatives of all metabolites are practically zero.

Given that the cellular metabolic response depends on the extracellular concentrations of insulin, glucagon and all exchangeable external metabolites, we were confronted with a quasi-continuum of external conditions at which load characteristics can be constructed. Therefore, we decided to choose two different types of external conditions. For load characteristics at varying plasma levels of glucose, we used the phenomenological transfer functions, glucose-hormone transfer and hormone-phosphorylation transfer function (see Materials and Methods) to compute the plasma concentrations of insulin and glucagon from the plasma glucose level and the phosphorylation state of hormone-sensitive interconvertible enzymes. For all other load characteristics, we fixed the external conditions in strict correspondence to the assay conditions applied in the experiments that were used to calibrate the generic kinetic model, Hepatokin1. The external conditions for each load characteristic are given in Supporting Table S5.

Zonation of Carbohydrate Metabolism

The maximal gluconeogenetic capacity of PPHs and PCHs was analyzed by computing the exchange flux through the glucose transporter at varying concentrations
of the precursor metabolite, lactate (Fig. 3A). Given that lactate is converted to pyruvate, this calculation provides a realistic assessment of the gluconeogenetic capacity even under conditions where amino acids serve as the major gluconeogenetic substrate. PPHs are predicted to possess a significantly larger gluconeogenic capacity than PCH, and the maximal capacities of the two cell variants differ by more than a factor of 2. For both cell types, the half-maximal rate of gluconeogenesis is reached at lactate concentrations of ~1 mM, representing the normal physiological plasma value.

Differential capacities of gluconeogenesis and glycolysis in PPHs and PCHs have a large impact on glucose exchange with the blood. Figure 3B depicts the glucose exchange flux as a function of the external glucose concentration in a range between 3 and 12 mM, spanning physiological conditions from fasting (low insulin, high glucagon) to feeding (high insulin, low glucagon). PPHs are more responsive to changes in plasma glucose levels; that is, PPHs are more gluconeogenic at low glucose concentrations and become more glycolytic at high glucose concentrations. At physiological plasma concentrations of glucose in the range of 6–8 mM, PCHs are more glycolytic than PPHs. Importantly, the set point (i.e., the external glucose concentration at which the hepatocyte switches from glucose production to glucose consumption) shifts from 6.5 mM for PCHs to 8 mM for PPHs.

The capacity of PPH and PCH to metabolize glycerol and the two important food-derived monosaccharides, fructose and galactose, is depicted in Fig. 3C–E. Although there was no zonal difference in the glycerol uptake rate, PPHs had a higher capacity to metabolize fructose and galactose than PCHs. Figure 3F shows that the ability to store glycogen is equal in the two zones.

Zonation of Fatty Acid Metabolism

Zone-dependent differences in the metabolism of fatty acids were examined by computing the cellular uptake rate of free fatty acids (FFAs) and the rate of central pathways of lipid metabolism in dependence of external FFA concentrations (Fig. 4). Up to external concentrations of FFAs of ~0.8 mM, the uptake rate of FFAs is independent of the zonal localization.
of the hepatocyte. At higher plasma concentrations, the uptake rate of PCH reaches saturation, whereas the uptake capacity of PPHs does not. The same saturation kinetics in the load characteristics for PCHs were observed in the synthesis rate of triacylglycerol (TAG), the size of the TAG pool, and the synthesis rate of very-low-density lipoprotein (VLDL), which, however, differed only marginally in PPHs and PCHs at lower concentrations of FFAs. A stronger response of PCH to variations of external concentrations of FFAs was predicted for the \( \beta \)-oxidation of FFAs and the synthesis of ketone bodies.

Hepatic uptake of glucose and FFAs is counter-regulated. At low plasma glucose levels, the liver operates as a glucose producer, and lipolysis in adipose tissue increases the plasma level of FFAs and promotes their uptake into hepatocytes. At high plasma glucose levels, the liver operates as a glucose consumer, and the high insulin level promotes the uptake and esterification of FFAs in adipose tissue. This inverse relationship between the plasma glucose level and FFA uptake is reflected in the load characteristics shown in Fig. 4G. The load characteristics indicate that for glucose concentrations above 4 mM, PPHs and PCHs do not differ in the glucose-dependent uptake of FFAs. However, clear differences exist in the glucose dependency of FFA-utilizing pathways, such as the synthesis of cholesterol, FFAs, and VLDL. Generally, PPHs appear to possess a higher lipid-synthesizing capacity than PCHs. This is also reflected in a higher share of \textit{de novo} synthesized TAG (\textit{de novo lipogenesis}; DNL) in the total cellular TAG pool.

**Zonal Differences in Detoxification Capacities**

Clearance of potentially harmful metabolites from the blood is one of the most important liver functions. We analyzed the capability of PPHs and PCHs to extract ammonia and ethanol from the plasma. In the liver, ammonia can be fixed in the form of urea or glutamine. The urea cycle catalyzes
irreversible ammonia fixation, whereas ammonia fixation by glutamine synthesis is reversible, given that ammonia can be liberated from glutamine by glutaminases. Figure 5A–C depicts the rates of ammonia uptake, urea production, and glutamine synthesis in PPHs and PCHs at varying external ammonia concentrations. Averaged across the 6 animals, the ammonia uptake was ~4 times higher in PPHs and the metabolic fate of ammonia was completely different in the two cell fractions. Whereas PPHs fix the ammonia almost exclusively in the form of urea, PCHs have a very high rate of glutamine synthesis. No zone-dependent differences were obtained for ethanol detoxification.

**Zonal Differences in Energy Metabolism**

Given that PPHs and PCHs exhibit differences in central energy delivery and energy consumption pathways of carbohydrate, fatty acid, and ammonia metabolism, it seems obvious that there are also zonal differences in the energetic state of the two cell fractions. We thus analyzed the energetic state (measured by the adenylate charge and the ATP/ADP ratio), rate of gluconeogenesis, rate of ammonia detoxification, and rate of TAG synthesis in response to varying oxygen concentrations (Fig. 6A–H). Our computations predicted a significantly lower ATP/ADP ratio and adenylate charge of PCHs than of PPHs. Gluconeogenesis of PCHs was also more sensitive to falling oxygen pressure. Generally, all metabolic functions become independent of oxygen pressure at pO₂ >25 mm Hg because of oxygen saturation of complex IV of the respiratory chain.

**Discussion**

**METABOLIC ZONATION: THE QUANTITATIVE VIEW**

The aim of our work was to unravel the functional implications of the heterogeneous allocation of protein mass to the central metabolism of hepatocytes residing in the portal and central regions of the acinus. Numerous articles have already reported on the zonation of metabolic enzymes revealed at the transcriptional and translational levels of gene expression or by directly assaying enzyme activities. However, inferring from such data the flux changes of the related metabolic pathways is problematic in view of the enzyme-regulatory mechanisms operating after gene expression. Therefore, we have chosen an approach that combines experimentally determined protein abundances in zone-specific cell fractions with a kinetic model of hepatocyte metabolism that has been extensively validated based on metabolic experiments with hepatocytes, liver tissue, and perfused livers. This approach enabled us to overcome the conventional, ontology-based classification of zone-dependent pathway capacities into “higher or lower or equal” by a quantitative assessment of cell functions in response to typical changes of the blood plasma.
During the past two decades, successful attempts to isolate pure hepatocyte populations from whole liver by flow cytometry have been made, (17-20) overcoming hurdles such as the vast hepatocyte size and intense autofluorescence. However, up to now, flow cytometry has been used predominantly for the isolation and study of hepatocyte populations derived from the whole liver, and early attempts at the acinar zone-specific isolation of hepatocytes by cell sorting did not prevail. (21) More recently, imaging techniques, such as immunohistochemistry and in situ hybridization, have been developed, enabling the isolation of cells based on the presence of specific marker proteins. (22) For the separation of hepatocytes from the PP and PC regions by flow cytometry, we exploited the fact that surface protein E-Cad and the metabolic enzyme, GLUL, are strictly zonated in the mouse acinus. (23,24) The analysis of the proteomic data of our sorted cells confirms the classical pericentral zonated proteins such as GLUL, ornithine aminotransferase (OAT), cytochrome P450 family 7 subfamily A member 1 (Cyp7A1) as well as many proteins of drug metabolism (e.g., CYP2E1, CYP1A2, and cytochrome P450, family 2, subfamily c, polypeptide 29 [CYP2C29]) for which heterogeneous distribution has been known for many years. (25,26) The PP fraction also contains the classical representatives, such as histidine ammonia lyase (HAL), mitochondria proteins like sideroflexin 1 (SFXN1), cytochrome C oxidase subunit 7A1 (COX7A1), (5,27) as well as hydroxysteroid 17-beta dehydrogenase 6 (HSD17B6) and polymeric immunoglobulin receptor (PIGR). (29) In addition, the analyses also show a clear zonation of proteins, that the heterogeneous distribution of which along the liver acinus has not been known, such as galectin 1 (LGASL1) and polymeric immunoglobulin receptor (PIGR). (29) In addition, the analyses also show a clear zonation of proteins, that the heterogeneous distribution of which along the liver acinus has not been known, such as galectin 1 (LGASL1) as well as shroom family member (SHROOM), in the PCH fraction. However, if looking at the functions of these proteins, it does not seem so unlikely that they are subject to a clear zonation. For example, the strongly zoned expression of galectin could also be confirmed by its function as an immune/inflammatory regulator which acts both extra- and intracellularly, modulating innate and adaptive immune responses. (30) In the past decade, evidence shows that many processes of innate immunity...
immunity are also not homogeneously distributed in the liver. In this regard, MacParland et al. could show that the PC localized endothelial cells probably have the largest proportion of the innate immune response in the healthy liver.\(^{31}\) Taken together, this separation technique improved the specificity of isolated hepatocytes from the different zones compared to the commonly used digitonin-collagenase perfusion.\(^{32}\) Proteomics-based determination of enzyme abundances in the separate cell fractions and usage of protein abundances in an advanced kinetic model of hepatocyte metabolism enabled us to make in silico predictions of the metabolic performance of PPHs and PCHs. The results obtained by our systems biology approach confirmed some already-known features and revealed additional features underlying the “division of labor”\(^{10}\) in liver metabolism.

**CARBOHYDRATE METABOLISM**

Earlier studies on the zonation of carbohydrate metabolism in the liver have provided evidence that PPHs and PCHs differ in their gluconeogenic and glycolytic capacities.\(^{6,33}\) However, the extent of these zone-dependent differences is now known to be highly dynamic, depending, for example, on nutritional state and circadian rhythms.\(^{34}\) In concordance with results in an earlier work,\(^{35}\) our data suggest that both populations of hepatocytes act as a “glucostat,”\(^{36}\) producing glucose when blood glucose levels are below a critical set point (fasting) and utilizing glucose when blood glucose levels are above the set point (e.g., after a meal; see Fig. 3B). In agreement with literature data, our model computations suggest that PCHs are more glycolytic than PPHs. In PPHs, the protein abundances of the lactate transporter, glucose transporter 2 (GLUT2), and PCJP, as well as key regulatory enzymes of gluconeogenesis, such as phosphoenolpyruvate carboxylase, fructose bisphosphatase 2/phosphofructokinase 2, and glucokinase, are higher than in PCHs. In line with this, Ogawa et al.\(^ {37}\) found a stronger expression of the insulin-independent, but concentration-dependent, glucose transporter, GLUT2, in PPHs.

Gluconeogenesis from lactate is reported to be more prominent in PPHs.\(^ {38}\) This is confirmed by our computations, suggesting a remarkably diminished gluconeogenic capacity of PCHs (Fig. 3A). Our computations also suggest zone-dependent differences in the utilization of the two important food-derived monosaccharides, galactose and fructose (see Fig. 3D,E). Several enzymes involved in the metabolism of these monosaccharides, such as aldolase B (portal/central abundance ratio, \(R = 2.48\)), triose kinase (\(R = 1.88\)), GLUT2 (\(R = 1.9\)), fructokinase (\(R = 1.28\)), and the galactose transporter (\(R = 1.9\)), have a higher abundance in cells within the PP region.

**LIPID METABOLISM**

Fatty acids formed de novo (DNL), by lipolysis of TAG stores in lipid droplets or taken up from the plasma, can be used to yield acetyl-CoA in the process of β-oxidation or can be esterified with glycerol to form TAG stored in lipid droplets or lipoproteins (VLDL). Our analysis revealed almost identical uptake rates of FFAs up to plasma concentrations of ~0.8 mM, which is higher than the values observed in C57Bl/6N mice under an oral fat load.\(^ {39}\) Thus, the observation that the accumulation of fat (steatosis) in adults starts preferentially in the PC region cannot be explained simply by differences in the capacity of PPHs and PCHs. It should be noted, however, that we have assessed the uptake rate of FFAs under conditions of very low external glucose concentrations also applied in related in vitro experiments.

Another source for hepatic fatty acids is DNL from cytosolic acetyl-CoA derived from citrate by the ATP-dependent citrate, lyase. Our analysis suggests that PPHs synthesize more FFAs and possess a higher fraction of synthesized TAG attributable to the higher abundance of fatty acid synthase (PP/PC, \(R = 1.4\)), acetyl-CoA carboxylase (\(R = 1.2\)), and ATP citrate lyase (\(R = 2.8\)) compared with PPHs. The literature findings on the zonation of DNL are contradictory. Our results are in line with those of Evans et al.,\(^ {40}\) who showed a preponderance of all three mentioned enzymes in the PPHs. However, the majority of publications conclude that DNL is more pronounced in PCHs.\(^ {41}\) It is important to note that the relative contribution of DNL to the total pool of cellular fatty acids depends strongly upon the external glucose concentration. A steep increase in DNL occurs at high external glucose concentrations when plasma concentrations of FFAs are low and the uptake rate of fatty acids is low in both PPHs and PCHs (Fig. 4J).

Regarding the synthesis and export of VLDL, our analysis predicts a strong increase with increasing
concentrations of FFAs in concordance with previous findings.\(^{42-44}\) The export capacity for VLDL of PPH exceeds that of PCH regardless of the fatty acid uptake rate (Fig. 4D). In particular, at low glucose, the VLDL release rate in PPHs is significantly higher than in PCHs. This model-based prediction is supported by the fact that some marker proteins involved in the assembly and secretion of VLDL particles are enriched in PPHs, including microsomal triglyceride transfer protein (PP:PC, R = 1.24), protein disulfide-isomerase A (R = 2.1), and vesicle-trafficking protein SEC22 homolog B (R = 1.6).

Likewise, we found higher rates of cholesterol synthesis in PPHs than in PCHs (Fig. 4H). In agreement with this finding, Cheng et al.\(^{43}\) also found a predominance of cholesterol synthesis in the PP zone. Moreover, Li et al.\(^{45}\) and Singer et al.\(^{46}\) reported that hydroxymethylglutaryl coenzyme A reductase, the main regulatory enzyme of cholesterol synthesis,\(^{11}\) is almost exclusively found in the first hepatocytes in the PP area. A higher capacity for cholesterol synthesis in PPHs than in PCHs fits well with the higher VLDL secretion rates, given that cholesterol and cholesterol esters are major constituents of VLDL particles. The higher capacity of PPHs than PCHs to export TAG in terms of VLDL could also explain the disease pattern of early hepatic steatosis in adults, which is predominantly PC centered.\(^{41,47}\) Understanding differences in the lipid metabolism of PPHs and PCHs in vivo also requires taking into account portocentral differences in the sinusoidal blood flow and plasma concentration of metabolites (in particular oxygen, glucose, and FFAs) and hormones.

AMMONIA METABOLISM

In addition to the zonal effects of carbohydrate metabolism, the ammonia detoxification is the best examined zonated liver function. The liver possesses two alternative pathways for ammonia detoxification, which are strictly separated along the portocentral axis: conversion to urea or glutamine. This view is confirmed by our analysis. Interestingly, the total capacity for ammonia detoxification in the physiological range (plasma levels of ammonia <0.5 mM) is almost the same in the two zones (Fig. 5A). That is, despite large zonal differences in the capacity of the urea cycle and glutamine synthesis, significant portocentral differences in the total ammonia-detoxifying capacity are expected for external ammonia concentrations that lie far above the physiological value of ~80 \(\mu M\) in mice.\(^{48}\) In the PP zone, ammonia detoxification is achieved almost exclusively by urea formation, whereas in the PC zone, glutamine synthesis accounts for almost all ammonia removal. The strict division of ammonia detoxification between the urea cycle and GLUL fits in with the work of Braeuning et al.,\(^{29}\) who found a complete lack of GLUL in the PP zone and a preferential location (PP/PC abundance ratios of 1.5-1.77:1) of mRNAs of urea cycle enzymes (ornithine transcarbamylase, argininosuccinic acid synthetase, argininosuccinic acid lyase, and arginase) in the PP area. We found protein abundance ratios of 0.84, 1.64, and 4.72 for the three enzymes. More importantly, CPS1, the main regulatory enzyme of the urea cycle, occurs with 2.76-fold higher abundance in the PP zone than in the PC zone.

ENERGY METABOLISM

Hitherto, little was known about the zonal distribution of adenine nucleotides and energetic state between the PP and PC zones. The proteomics data point to an increased capacity of PPHs, compared to PCHs, to generate ATP by oxidative phosphorylation because of the increased abundance of some proteins of the respiratory chain, including complexes I-IV (R = 1.2-2.2), F0F1-ATPase (R = 1.76), adenine nucleotide translocator (R = 1.73), and mitochondrial phosphate exchanger (R = 1.53). The better endowment of PPHs with proteins of oxidative phosphorylation does not necessarily imply a higher ATP level, given that PPHs also have a higher capacity for excessively ATP-demanding processes, such as gluconeogenesis and urea synthesis, than PCHs. Balancing the opposing facts against each other, the model computations suggest a higher adenylate charge as well as a higher ATP/ADP ratio in PPHs than in PCHs. This finding is in agreement with the portal-to-central declining ATP level measured in a millifluidic media perfusion system that enables cells to be cultured in a slow-flow environment. Closer inspection of the regulatory circuits entailing this energetic difference between PPHs and PCH yields the following explanation: mutual regulation of fatty acid oxidation and aerobic glycolysis as the main source of ATP production proceeds by reduced nicotinamide adenine dinucleotide– and
acetyl-CoA–dependent inhibition of the pyruvate dehydrogenase (PDHC) reaction, the entry point of glucose-derived carbons into the citric acid cycle. At reduced rates of β-oxidation, rising nicotinamide adenine dinucleotide and CoA levels activate PDHC, rendering glycolytic pyruvate the prevailing energy-delivering substrate. The switch from fatty acids to glucose goes along with a falling mitochondrial redox state and a transient and moderate down-regulation of the respiratory chain and ATP production rate that is subsequently compensated for by a kinetic up-regulation of the respiratory chain as a consequence of the reduced ATP level. Therefore, the computed zonal differences in ATP levels reflect zonal differences in substrate preference rather than in the local energy demand of hepatocytes.

ETHANOL METABOLIZATION

In the healthy liver, ethanol is predominantly degraded by alcohol dehydrogenase (ADH), converting ethanol to acetaldehyde and the acetaldehyde dehydrogenase (ALDH) converting acetaldehyde 1 to acetate. Zone-dependent expression differences with a PP:PC value of R = 1.6 for ADH has been reported by Salsano et al., whereas our data yield R = 1.2 for ADH and R = 0.45-4.50 for mitochondrial ALDHs. Based on these zone-dependent expression differences, our model yielded only marginal differences in the ethanol detoxification capacities of PPHs and PCHs (Fig. 5D).

METABOLIC CAPACITIES OF THE INTERMEDIATE ZONE

While the focus of our study was clearly on the elucidation of possible metabolic differences between the periportal and pericentral zone, we also analyzed the metabolic capacities of E-Cad-negative and chondroitin sulfate-negative cells stemming from the intermediate zone (preliminary data given in Supporting Table S6). These preliminary results suggest that the intermediate zone has comparable capacities for the uptake and release of glucose as the PC zone whereas the uptake capacities for fructose and galactose correspond to those of the PP zone. The capacities for TAG synthesis and VLDL export were higher and the capacity for β-oxidation was slightly lower than in the PP and PC zones. Ammonia uptake and metabolization were comparable to the PP zone, whereas ethanol detoxification was constant throughout all three zones. The capacities for the synthesis of fatty acid and cholesterol synthesis were just between those of the PP and PC zone.

Our analysis shows that PPHs and PCHs exhibit significant differences in the protein abundance of approximately two-thirds of metabolic enzymes. These differences result from the fact that extracellular conditions, (e.g., nutrients and hormones), have a strong impact on gene expression, which vary along the sinusoidal bloodstream. Our model-based analysis suggests that the functional differences implied by unequal enzyme abundances along the porto-central axis depend essentially on the actual plasma concentrations of metabolites and hormones. For example, despite large zonal differences in the capacity of the urea cycle and glutamine synthesis, significant porto-central differences in the total ammonia-detoxifying capacity are only expected for external ammonia concentrations that are far above the physiological value. Similarly, clear discrepancies in TAG synthesis and VLDL export are predicted to occur at FFA concentrations above the physiological value of ~1 mM. Generally, it appears that portal-to-central differences in liver metabolism become more pronounced if the plasma concentrations of glucose and FFAs start to deviate from their physiological values. It must be emphasized that this conclusion holds only for short-time deviations where the liver’s proteome does not adapt to a nutritional status that is different from the well-fed nutritional status of the mice in our study.

How variable gene expression will change the metabolic performance of PPHs and PCHs under diabetes, hyperammonia, or dyslipidemia still remains to be addressed to gain a comprehensive mechanistic view of liver metabolism.

Acknowledgment: We thank Katrin Jäger and Andreas Lösche from the Core Unit Fluorescence Technologie at Leipzig University for technical guidance and establishing of the flow cytometry experiments. Furthermore, we thank Prof. Rolf Gebhardt for his valuable comments and recommendations regarding the establishment of fluorescent-activated cell sorting analysis methods. Gratitude is also expressed for the excellent technical assistance of Doris Mahn and Vivien Teßmar. Furthermore, we thank Dr. Petra Hirrlinger from the
Medizinisches Experimentelles Zentrum (Faculty of Medicine) for taking excellent care of the mice.

**Author Contributions:** N.B., H.G.H., and M.M.-S. made substantial contributions to conception and design; E.K. R.G., J.E., F.O., and D.M. to acquisition, analyses, and interpretation of the data; F.O. to revising the article critically for important intellectual content; and N.B., H.G.H. and M.M.-S. to final approval of the version to be published.

**REFERENCES**

1. Mathew P, Thoppil D. Hypoglycemia. Treasure Island, FL: StatPearls; 2020.
2. Holecek M. Evidence of a vicious cycle in glutamine synthesis and breakdown in pathogenesis of hepatic encephalopathy—therapeutic perspectives. Metab Brain Dis 2014;29:9-17.
3. Schliess F, Hoehme S, Henkel SG, Ghiballah A, Driesch D, Böttger J, et al. Integrated metabolic spatial-temporal model for the prediction of ammonia detoxification during liver damage and regeneration. Hepatology 2014;60:2040-2051.
4. Kietzmann T. Metabolic zonation of the liver: the oxygen gradient revisited. Redox Biol 2017;11:622-630.
5. Gebhardt R, Matz-Soja M. Liver zonation: novel aspects of its regulation and its impact on homeostasis. World J Gastroenterol 2014;20:8491-8504.
6. Jungermann K. Functional significance of hepatocyte heterogeneity for glycolysis and gluconeogenesis. Pharmacol Biochem Behav 1983;18:409-414.
7. Kang YB, Eo J, Mert S, Yarmush ML, Usta OB. Metabolic patterning on a chip: towards in vitro liver zonation of primary rat and human hepatocytes. Sci Rep 2018;8:8951.
8. Tomlinson L, Hyndman L, Firman JW, Bentley R, Kyffin JA, Webb SD, et al. In vitro liver zonation of primary rat hepatocytes. Front Bioeng Biotechnol 2019;7:17.
9. Berndt N, Holzhuetter HG. Dynamic metabolic zonation of the hepatic glucose metabolism is accomplished by sinusoidal plasma gradients of nutrients and hormones. Front Physiol 2018;9:1786.
10. Halpern KB, Shenhav R, Matcowsitch-Natan O, Törb H, Lemze D, Golan M, et al. Single-cell spatial reconstruction reveals global division of labour in the mammalian liver. Nature 2017;542:352-356.
11. Berndt N, Bulik S, Wallach I, Wünsch T, König M, Stockmann M, et al. HEPATOKIN1 is a biochemistry-based model of liver metabolism for applications in medicine and pharmacology. Nat Commun 2018;9:2386.
12. Gebhardt R, Hengstler JG, Muller D, Glockner R, Buenning P, Laube B, et al. New hepatocyte in vitro systems for drug metabolism: metabolic capacity and recommendations for application in basic research and drug development, standard operation procedures. Drug Metab Rev 2003;35:145-213.
13. Matz-Soja M, Akefie S, Marbach E, Böttger J, Arnold K, Schmidt-Heck W, et al. Hepatic Hedgehog signaling contributes to the regulation of IGF1 and IGFBP1 serum levels. Cell Commun Signal 2014;12:11.
14. Burke ZD, Reed KR, Phesse TJ, Sansom OJ, Clarke AR, Tosh D. Liver Zonation occurs through a β-catenin-dependent, c-Myc-independent mechanism. Gastroenterology 2009;136: 2316-2324.e3.
15. Gaasbeek Janzen JW, Gebhardt R, ten Voorde GH, Lamers WH, Charles R, Moorman AF. Heterogeneous distribution of glutamine synthetase during rat liver development. J Histochem Cytochem 1987;35:49-54.
16. Bulik S, Holzhuetter H-G, Berndt N. The relative importance of kinetic mechanisms and variable enzyme abundances for the regulation of hepatic glucose metabolism—insights from mathematical modeling. BMC Biol 2016;14:415.
17. Black KA, Novicki DL, Vincent JL, Smith GJ. Flow cytometric analysis of xenobiotic metabolism activity in isolated rat hepatocytes. Cytometry 1993;14:334-338.
18. Sevegnini M, Sherman J, Seegal A, Jayaprakash NK, Aubin J, Wang G, et al. A rapid two-step method for isolation of functional primary mouse hepatocytes: cell characterization and analysis of glycglycoprotein receptor based assay development. Cytotechnology 2011;64:187-195.
19. Wyman J, Guertin F, Mansour S, Fournier M, Laliberté S. Use of mouse hepatocytes for the flow cytometric determination of DNA levels of nuclei extracted from fresh tissue of hybrid larch (Larix x eurolepis Henry). Cytometry 1993;14:217-222.
20. Gonçalves LA, Vigário AM, Penha-Gonçalves C. Improved isolation of murine hepatocytes for in vitro malaria liver stage studies. Malaria J 2007;6:169.
21. Thalhammer T, Gesl A, Braakman I, Graf J. Separation of hepatocytes of different acinar zones by flow cytometry. Cytometry 1989;10:772-778.
22. Haroon MF, Skennerton CT, Steen JA, Lachner N, Hugenholz P, Tyson GW. In-solution fluorescence in situ hybridization and fluorescence-activated cell sorting for single cell and population genome recovery. Methods Enzymol 2013;533:3-19.
23. Gebhardt R, Mecke D. Heterogeneous distribution of glutamine synthetase among rat liver parenchymal cells in situ and in primary culture. EMBO J 1983;2:567-570.
24. Doi Y, Tamura S, Nammo T, Fukui K, Kiso S, Nagafuchi A. Development of complementary expression patterns of E- and N-cadherin in the mouse liver. Hepatol Res 2007;37:230-237.
25. Monga SPS, ed. Molecular Pathology of Liver Diseases. Boston, MA: Springer Science+Business Media; 2011.
26. Ben-Moshe S, Shirapa Y, Moor AE, Manco R, Veg T, Bahar Halpern K, et al. Spatial sorting enables comprehensive characterization of liver zonation. Nat Metab 2019;1:899-911.
27. Rönnt P, Poulsen P, Hansson O, Holmkrist J, Ålengren P, Nilsson P, et al. Age influences DNA methylation and gene expression of COX7A1 in human skeletal muscle. Diabetologia 2008;51:1159-1168.
28. Cheng X, Kim SY, Okamoto H, Xio Y, Yancopoulos GD, Murphy AJ, et al. Glucagon contributes to liver zonation. Proc Natl Acad Sci U S A 2018;115:E4111-E4119.
29. Braeuning A, Ittrich C, Kohle C, Hallfinger S, Bonin M, Buchmann A, et al. Differential gene expression in peripheral and perivascular mouse hepatocytes. FEBS J 2006;273:5051-5061.
30. Potikha T, Ella E, Cerliani JP, Mizrahi L, Pappo O, Rabinovich GA, et al. Galectin-1 is essential for efficient liver regeneration following hepatectomy. Oncotarget 2016;7:31738-31754.
31. MacParland SA, Liu JC, Ma ZX, Innes BT, Bartczak AM, Gage BK, et al. Single cell RNA sequencing of human liver reveals distinct intrahepatic macrophage populations. Nat Commun 2018;9:4383.
32. Strain AJ. Isolated hepatocytes: use in experimental and clinical hepatology. Gut 1994;35:433-436.
33. Guder WG, Schmidt U. Liver cell heterogeneity. The distribution of pyruvate kinase and phosphoenolpyruvate carboxykinase (GTP) in the liver lobule of fed and starved rats. Hoppe Seylers Z Physiol Chem 1976;357:1793-1800.
34. Froy O. The relationship between nutrition and circadian rhythms in mammals. Front Neuroendocrinol 2007;28:61-71.
35. Berndt N, Horger MS, Bulik S, Holzhuetter HG. A multiscale modelling approach to assess the impact of metabolic zonation
and microperfusion on the hepatic carbohydrate metabolism. PLoS Comput Biol 2018;14:e1006005.

36) Jungermann K. Metabolische Zonierung des Leberparenchym (Metabolic Zonation of Liver Parenchyma). Die Naturwissenschaften 1985;72:76-84.

37) Ogawa A, Kurita K, Ikezawa Y, Igarashi M, Kuzumaki T, Daimon M, et al. Functional localization of glucose transporter 2 in rat liver. J Histochem Cytochem 1996;44:1231-1236.

38) Bracht A, Constantin J, Ishii-Iwamoto EL, Suzuki-Kemmelmier F. Zonation of gluconeogenesis from lactate and pyruvate in the rat liver studied by means of anterograde and retrograde bivascular perfusion. Biochim Biophys Acta 1994;1199:298-304.

39) Yeh MM, Brunt EM. Pathological features of fatty liver disease. Gastroenterology 2014;147:754-764.

40) Evans JL, Quistorff B, Witthers LA. Zonation of hepatic lipogenic enzymes identified by dual-digitonin-pulse perfusion. Biochem J 1989;259:821-829.

41) Schleicher J, Tokarski C, Marbach E, Matz-Soja M, Zellmer S, Gebhardt R, et al. Zonation of hepatic fatty acid metabolism—the diversity of its regulation and the benefit of modeling. Biochim Biophys Acta 2015;1851:641-656.

42) Aarsland A, Wolfe RR. Hepatic secretion of VLDL fatty acids during stimulated lipogenesis in men. J Lipid Res 1998;39:1280-1286.

43) Cheng HC, Yang CM, Shiao MS. Zonation of cholesterol and glycerolipid synthesis in regenerating rat livers. HEPATOLOGY 1993;17:280-286.

44) Franke H, Pottatz I, Dargel R. Zonal differences in lipoprotein formation in the thioacetamide-induced micronodular-cirrhotic rat liver. Experi Toxicol Pathol 1994;46:503-511.

45) Li AC, Tanaka RD, Callaway K, Fogelman AM, Edwards PA. Localization of 3-hydroxy-3-methylglutaryl CoA reductase and 3-hydroxy-3-methylglutaryl CoA synthase in the rat liver and intestine is affected by cholestyramine and mevinolin. J Lipid Res 1988;29:781-796.

46) Singer II, Kawka DW, Kazazis DM, Alberts AW, Chen JS, Huff JW, et al. Hydroxymethylglutaryl-coenzyme A reductase-containing hepatocytes are distributed periportally in normal and mevinolin-treated rat livers. Proc Natl Acad Sci U S A 1984;81:5556-5560.

47) Takahashi Y, Fukusato T. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol 2014;20:15539-15548.

48) Koizumi T, Hayakawa J, Nikaido H. Blood ammonia concentration in mice: normal reference values and changes during growth. Lab Anim Sci 1990;40:308-311.

49) Salsano F, Maly IP, Sasse D. The circadian rhythm of intra-acinar profiles of alcohol dehydrogenase activity in rat liver: a micro-quantitative study. Histochem J 1990;22:395-400.

50) Fernandez J, Valdeolmillos M. Increased levels of free fatty acids in fasted mice stimulate in vivo beta-cell electrical activity. Diabetes 1998;47:1707-1712.

Supporting Information

Additional Supporting Information may be found at onlinelibrary.wiley.com/doi/10.1002/hep.31274/suppinfo.